- Home
- ABSI vs ORIC Comparison
ABSI vs ORIC Comparison
Compare ABSI & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABSI
- ORIC
- Stock Information
- Founded
- ABSI 2011
- ORIC 2014
- Country
- ABSI United States
- ORIC United States
- Employees
- ABSI N/A
- ORIC N/A
- Industry
- ABSI Biotechnology: Pharmaceutical Preparations
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- ABSI Health Care
- ORIC Health Care
- Exchange
- ABSI Nasdaq
- ORIC Nasdaq
- Market Cap
- ABSI 353.8M
- ORIC 362.9M
- IPO Year
- ABSI 2021
- ORIC 2020
- Fundamental
- Price
- ABSI $2.65
- ORIC $8.17
- Analyst Decision
- ABSI Strong Buy
- ORIC Strong Buy
- Analyst Count
- ABSI 5
- ORIC 8
- Target Price
- ABSI $8.40
- ORIC $18.83
- AVG Volume (30 Days)
- ABSI 2.9M
- ORIC 1.6M
- Earning Date
- ABSI 05-13-2025
- ORIC 05-05-2025
- Dividend Yield
- ABSI N/A
- ORIC N/A
- EPS Growth
- ABSI N/A
- ORIC N/A
- EPS
- ABSI N/A
- ORIC N/A
- Revenue
- ABSI $4,815,000.00
- ORIC N/A
- Revenue This Year
- ABSI $145.79
- ORIC N/A
- Revenue Next Year
- ABSI $99.29
- ORIC N/A
- P/E Ratio
- ABSI N/A
- ORIC N/A
- Revenue Growth
- ABSI N/A
- ORIC N/A
- 52 Week Low
- ABSI $2.01
- ORIC $3.90
- 52 Week High
- ABSI $6.33
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- ABSI 40.44
- ORIC 72.38
- Support Level
- ABSI $2.56
- ORIC $5.52
- Resistance Level
- ABSI $2.84
- ORIC $8.44
- Average True Range (ATR)
- ABSI 0.20
- ORIC 0.63
- MACD
- ABSI -0.01
- ORIC 0.32
- Stochastic Oscillator
- ABSI 8.26
- ORIC 93.11
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.